[Amineptine and amotival syndrome (author's transl)].
Intellectual, affective and motor inhibition is part of the syndrome encountered in: drug withdrawal in addicts especially with opiates; hebephrenia. Amineptine a new antidepressant agent with psychoanaleptic properties has been studied in these patients. Considering this psychotonic activity was logical to test both the tolerance of this compound in drug addicts and the risk of delirious reactivation in schizophrenic patients. The open study in 19 patients shows an effect of amineptine: -on inhibition and loss of activity, apragmatism and deterioration of social behaviour; -a subjective improvement of intellectual performance. And moreover: without reactivation of preexisting delirious ideas in schizophrenic patients; without drug addiction in treated toxicomaniacs.
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003986:Dibenzocycloheptenes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007266:Inhibition, Psychological; D008297:Male; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000150:complications; D012562:Schizophrenia, Disorganized / Q000188:drug therapy* / Q000523:psychology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology
D000929:Antidepressive Agents, Tricyclic; D003986:Dibenzocycloheptenes; C011597:amineptin
Etude préliminaire en ouvert de l'amineptine sur le syndrome déficitaire des hébéphrènes et des toxicomanes au décours du sevrage.